JP2018505199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505199A5 JP2018505199A5 JP2017542048A JP2017542048A JP2018505199A5 JP 2018505199 A5 JP2018505199 A5 JP 2018505199A5 JP 2017542048 A JP2017542048 A JP 2017542048A JP 2017542048 A JP2017542048 A JP 2017542048A JP 2018505199 A5 JP2018505199 A5 JP 2018505199A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- crystalline
- accordance
- data substantially
- diffraction data
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012453 solvate Substances 0.000 claims 21
- 238000002447 crystallographic data Methods 0.000 claims 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 6
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 claims 2
- 150000004682 monohydrates Chemical group 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 1
- 229940011051 isopropyl acetate Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical group CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115674P | 2015-02-13 | 2015-02-13 | |
| US62/115,674 | 2015-02-13 | ||
| PCT/IB2016/050755 WO2016128936A1 (en) | 2015-02-13 | 2016-02-12 | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505199A JP2018505199A (ja) | 2018-02-22 |
| JP2018505199A5 true JP2018505199A5 (enExample) | 2019-03-22 |
Family
ID=55359562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542048A Pending JP2018505199A (ja) | 2015-02-13 | 2016-02-12 | （Ｓ）−５−ベンジル−Ｎ−（５−メチル−４−オキソ−２，３，４，５テトラヒドロベンゾ［ｂ］［１，４］オキサゼピン−３−イル）−４Ｈ−１，２，４−トリアゾール−３−カルボキサミドの結晶形 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10287280B2 (enExample) |
| EP (1) | EP3256467A1 (enExample) |
| JP (1) | JP2018505199A (enExample) |
| KR (1) | KR20170117472A (enExample) |
| CN (1) | CN107207485A (enExample) |
| AU (1) | AU2016217496B2 (enExample) |
| BR (1) | BR112017017411A2 (enExample) |
| CA (1) | CA2976172A1 (enExample) |
| IL (1) | IL253731A0 (enExample) |
| RU (1) | RU2017131862A (enExample) |
| WO (1) | WO2016128936A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017069279A1 (ja) | 2015-10-23 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| LT3552017T (lt) | 2016-12-09 | 2022-05-10 | Denali Therapeutics Inc. | Junginiai, naudotini kaip ripk1 inhibitoriai |
| WO2019123219A1 (en) * | 2017-12-20 | 2019-06-27 | Glaxosmithkline Intellectual Property Development Limited | Crystalline salt form of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| SI3788044T1 (sl) | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
| PL3788045T3 (pl) | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
| US20220218719A1 (en) * | 2019-05-17 | 2022-07-14 | Glaxosmithkline Intellectual Property Development Limited | Matrix composition comprising (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| ES3043457T3 (en) | 2019-09-06 | 2025-11-25 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
| AU2020341708B2 (en) | 2019-09-06 | 2024-01-04 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| SMT202600151T1 (it) | 2019-11-07 | 2026-05-12 | Rigel Pharmaceuticals Inc | Composti eterociclici inibitori di rip1 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
-
2016
- 2016-02-12 EP EP16704713.3A patent/EP3256467A1/en not_active Withdrawn
- 2016-02-12 JP JP2017542048A patent/JP2018505199A/ja active Pending
- 2016-02-12 BR BR112017017411A patent/BR112017017411A2/pt not_active Application Discontinuation
- 2016-02-12 US US15/548,500 patent/US10287280B2/en active Active
- 2016-02-12 RU RU2017131862A patent/RU2017131862A/ru not_active Application Discontinuation
- 2016-02-12 AU AU2016217496A patent/AU2016217496B2/en not_active Ceased
- 2016-02-12 KR KR1020177025358A patent/KR20170117472A/ko not_active Withdrawn
- 2016-02-12 CA CA2976172A patent/CA2976172A1/en not_active Abandoned
- 2016-02-12 WO PCT/IB2016/050755 patent/WO2016128936A1/en not_active Ceased
- 2016-02-12 CN CN201680010191.7A patent/CN107207485A/zh active Pending
-
2017
- 2017-07-30 IL IL253731A patent/IL253731A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017131862A (ru) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ (S)-5-БЕНЗИЛ-N-(5-МЕТИЛ-4-ОКСО-2,3,4,5-ТЕТРАГИДРОБЕНЗО[b][1,4]ОКСАЗЕПИН-3-ИЛ)-4H-1,2,4-ТРИАЗОЛ-3-КАРБОКСАМИДА | |
| HRP20210748T1 (hr) | Postupak priprave spojeva s aktivnošću inhibitora hiv integraze | |
| JP2018024682A5 (enExample) | ||
| CN112566907A (zh) | 作为ret抑制剂的吡唑衍生物 | |
| JP2022078315A5 (enExample) | ||
| JP2011510079A5 (enExample) | ||
| JP2008019161A5 (enExample) | ||
| RU2010145171A (ru) | Аналоги галихондрина в | |
| JP2018521020A5 (enExample) | ||
| JP2014063186A5 (enExample) | ||
| JP2012531408A5 (enExample) | ||
| JP2013532130A5 (enExample) | ||
| CN114206850A (zh) | 作为crac抑制剂的2h-苯并吡喃衍生物 | |
| JP2025111617A5 (enExample) | ||
| JP2015506987A5 (enExample) | ||
| RU2016118796A (ru) | Новая кристаллическая форма 2-{ 3-[2-(1-{ [3, 5-бис(дифторметил)-1н-пиразол-1-ил]ацетил} пиперидин-4-ил)-1, 3-тиазол-4-ил]-4, 5-дигидро-1, 2-оксазол-5-ил} -3-хлорфенилметансульфоната | |
| JP2015042663A5 (enExample) | ||
| JP2012508747A5 (enExample) | ||
| JP2010507590A5 (enExample) | ||
| JP2023508938A5 (enExample) | ||
| AR081659A1 (es) | Procedimiento de obtencion de la forma cristalina ii del febuxostat | |
| JP2016510767A5 (enExample) | ||
| JP2015038184A5 (enExample) | ||
| RU2016144187A (ru) | Твердые формы фармацевтически активного соединения | |
| JP2018009003A5 (enExample) |